NCT00439881View on ClinicalTrials.gov

A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2006

Conditions
Arthritis, RheumatoidInflammation
Interventions
DRUG

SB-681323

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY